INmune Bio, Inc. (INMB)
After hours:
| Previous close | 10.77 |
| Open | 10.46 |
| Bid | 9.99 x 100 |
| Ask | 10.08 x 100 |
| Day's range | 9.90 - 10.61 |
| 52-week range | 6.50 - 14.74 |
| Volume | |
| Avg. volume | 115,504 |
| Market cap | 198.005M |
| Beta (5Y monthly) | 1.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
Company to Host Conference Call Today, May 9, at 4:30pm ETBOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update. Q1 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): The AD02 randomized, blin
- GlobeNewswire
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 PM EDT to discuss results for its first quarter ended March 31, 2024 and to provide a corporate update. Co
- GlobeNewswire
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer’s Disease (AD) for more than three years under the Australian compassionate use program known as the Special A
